{"title": "PDF", "author": "PDF", "url": "https://www.uniklinik-freiburg.de/fileadmin/mediapool/07_kliniken/department_zkj/Studien/Neswletter_November_2022.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "1Newsletter\u00a0Klinische\u00a0Studien\u00a0\nZKJ\u2010Studienb\u00fcro\u00a0\u00a0\nVer\u00f6ffentlichung\u00a0von\u00a0Studienergebnissen\u00a0unter\u00a0Beteiligung\u00a0\ndes\u00a0ZKJ\u00a0\nRisk\u00a0for\u00a0severe\u00a0outcomes\u00a0of\u00a0COVI D\u201019\u00a0and\u00a0PIMS\u2010TS\u00a0in\u00a0children\u00a0with\u00a0SARS\u2010CoV\u20102\u00a0infection\u00a0in\u00a0\nGermany \u00a0\nSorg\u00a0AL,\u00a0Hufnagel\u00a0M,\u00a0Doenhardt\u00a0M,\u00a0Diffloth\u00a0N,\u00a0Schroten\u00a0H,\u00a0v.\u00a0Kr ies\u00a0R,\u00a0Berner\u00a0R,\u00a0Armann\u00a0J\u00a0(2022).\u00a0Eur\u00a0J\u00a0\nPediatr\u00a0181:3635\u201043.\u00a0doi:\u00a010.1007/s00431\u2010022\u201004587\u20105\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/35962242/ \u00a0\nAssociation\u00a0of\u00a0SARS\u2010CoV\u20102\u00a0Seropo sitivity\u00a0With\u00a0Myalgic\u00a0Encephalomyelitis\u00a0and/or\u00a0Chronic\u00a0\nFatigue\u00a0Syndrome\u00a0Among\u00a0Children\u00a0and\u00a0Adolescents\u00a0in\u00a0Germany\u00a0\nSorg\u00a0AL,\u00a0Becht\u00a0S,\u00a0Jank\u00a0M,\u00a0Armann\u00a0 J,\u00a0von\u00a0Both\u00a0U,\u00a0Hufnagel\u00a0M,\u00a0Lan der\u00a0F,\u00a0Liese\u00a0JG,\u00a0Niehues\u00a0T,\u00a0Verjans\u00a0E,\u00a0\nWetzke\u00a0M,\u00a0Stojanov\u00a0S,\u00a0Behrends\u00a0U,\u00a0 Drosten\u00a0C,\u00a0Schroten\u00a0H,\u00a0von\u00a0Kries\u00a0R\u00a0(2022).\u00a0JAMA\u00a0Netw\u00a0Open\u00a0\n5:e2233454.\u00a0doi:\u00a010.1001/jamanetworkopen.2022.33454\u00a0\n2Link\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/36166227/\u00a0\nSARS\u2010CoV\u20102\u00a0variants\u00a0and\u00a0the\u00a0risk \u00a0of\u00a0Pediatric\u00a0Inflammatory\u00a0Multisystem\u00a0Syndrome\u00a0\ntemporally\u00a0associated\u00a0with\u00a0SARS \u2010CoV\u20102\u00a0in\u00a0children\u00a0in\u00a0Germany \u00a0\nSorg\u00a0AL,\u00a0Siedler\u00a0A,\u00a0Doenhardt\u00a0M, \u00a0Schoenfeld\u00a0V,\u00a0Hufnagel\u00a0M,\u00a0Diff loth\u00a0N,\u00a0Berner\u00a0R,\u00a0von\u00a0Kries\u00a0R,\u00a0Armann\u00a0J\u00a0\n(2022).\u00a0Infection(Online\u00a0ahead \u00a0of\u00a0print);\u00a0doi:\u00a010.1007/s15010\u2010022\u201001908\u20106\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/36048361/\u00a0\nMental\u00a0health\u00a0of\u00a0children\u00a0with\u00a0a nd\u00a0without\u00a0special\u00a0healthcare\u00a0n eeds\u00a0and\u00a0of\u00a0their\u00a0caregivers\u00a0\nduring\u00a0COVID\u201019:\u00a0a\u00a0cross\u2010sectional\u00a0study  Geweniger\u00a0A,\u00a0Haddad\u00a0A,\u00a0Barth\u00a0M,\u00a0H\u00f6gl\u00a0H,\u00a0Mund\u00a0A,\u00a0Insan\u00a0\nS,\u00a0Langer\u00a0T.\u00a0BMJ\u00a0Paediatri cs\u00a0Open\u00a02022;6:e001509.\u00a0doi:\u00a010.1136/ bmjpo\u20102022\u2010001509\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/36053611/\u00a0\nLongitudinal\u00a0Immune\u00a0Response\u00a0to\u00a0Three\u00a0Doses\u00a0of\u00a0mRNA\u00a0Vaccine\u00a0Aga inst\u00a0COVID\u201019\u00a0in\u00a0\nPediatric\u00a0Patients\u00a0Receivi ng\u00a0Chemotherapy\u00a0for\u00a0Cancer \u00a0\nThomas\u00a0Lehrnbecher,\u00a0Ulrich\u00a0Sack, \u00a0Carsten\u00a0Speckmann,\u00a0Andreas\u00a0H\u00a0Groll,\u00a0Andreas\u00a0Boldt,\u00a0Benjamin\u00a0\nSiebald,\u00a0Simone\u00a0Hettmer,\u00a0Eva\u00a0Mari a\u00a0Demmerath,\u00a0Barbara\u00a0Schenk,\u00a0Sandra\u00a0Ciesek,\u00a0Jan\u00a0Henning\u00a0\nKlusmann,\u00a0Christian\u00a0Jassoy,\u00a0Sebas tian\u00a0Hoehl,\u00a0Clin\u00a0Infect\u00a0Dis202 2\u00a0Jul\u00a028;ciac570.\u00a0doi:\u00a0\n10.1093/cid/ciac570.\u00a0Onlin e\u00a0ahead\u00a0of\u00a0print.\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/35901198/\u00a0\nAusf\u00fchrlich:\u00a0s.\u00a0unten \u00a0\nSecukinumab\u00a0in\u00a0enthesitis\u2010related \u00a0arthritis\u00a0and\u00a0juvenile\u00a0psoriatic\u00a0arthritis:\u00a0a\u00a0randomised,\u00a0\ndouble\u2010blind,\u00a0placebo\u2010controlled, \u00a0treatment\u00a0withdrawal,\u00a0phase\u00a03 \u00a0trial\u00a0\nBrunner\u00a0HI,\u00a0Foeldvari\u00a0I,\u00a0Alexeeva\u00a0 E,\u00a0Ayaz\u00a0NA,\u00a0Calvo\u00a0Penades\u00a0I,\u00a0 Kasapcopur\u00a0O,\u00a0Chasnyk\u00a0VG,\u00a0Hufnagel\u00a0M,\u00a0\nZuber\u00a0Z,\u00a0Schulert\u00a0GS,\u00a0Ozen\u00a0S,\u00a0Ra khimyanova\u00a0A,\u00a0Ramanan\u00a0A,\u00a0Scott\u00a0 C,\u00a0Sozeri\u00a0B,\u00a0Zholobova\u00a0E,\u00a0Martin\u00a0R,\u00a0\nZhu\u00a0X,\u00a0Whelan\u00a0S,\u00a0Pricop\u00a0L,\u00a0Marti ni\u00a0A,\u00a0Lovell\u00a0DJ\u00a0and\u00a0Ruperto\u00a0N,\u00a0 on\u00a0behalf\u00a0of\u00a0Paediat ric\u00a0Rheumatology\u00a0\nINternational\u00a0Trials\u00a0Organizatio n\u00a0(PRINTO)\u00a0and\u00a0Pediatric\u00a0Rheuma tology\u00a0Collaborative\u00a0Study\u00a0Group\u00a0\n(PRCSG)\u00a0(2022).\u00a0Ann\u00a0Rheum\u00a0Dis\u00a0(Online\u00a0ahead\u00a0of\u00a0print);\u00a0https:// doi.org/10.1136/ard\u20102022\u2010222849)\u00a0\u00a0\nLink\u00a0zum\u00a0Artikel: \u00a0https://pubmed.ncbi.nlm.nih.gov/35961761/ \u00a0\nEffect\u00a0of\u00a0new\u00a0legislation\u00a0in\u00a0Ger many\u00a0on\u00a0prevalence\u00a0and\u00a0harm\u00a0of\u00a0 synthetic\u00a0cannabinoids.  \nSommer\u00a0MJ,\u00a0Halter\u00a0S,\u00a0Angerer\u00a0V,\u00a0Auw\u00e4rter\u00a0V,\u00a0Eyer\u00a0F,\u00a0Liebetrau\u00a0G ,\u00a0Ebbecke\u00a0M,\u00a0Hermanns\u2010Clausen\u00a0M.\u00a0\nClin\u00a0Toxicol\u00a0(Phila).\u00a02022\u00a0Oc t;60(10):1130\u20101138.\u00a0doi:\u00a010.1080/1 5563650.2022.2095282.\u00a0Epub\u00a02022\u00a0Sep\u00a0\n8. \nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/36074033/\u00a0\nEffect\u00a0of\u00a0nusinersen\u00a0on\u00a0motor,\u00a0respiratory\u00a0and\u00a0bulbar\u00a0function\u00a0 in\u00a0early\u2010onset\u00a0spinal\u00a0\nmuscular\u00a0atrophy \u00a0\nAstrid\u00a0Pechmann,\u00a0Max\u00a0Behrens,\u00a0Ka tharina\u00a0D\u00f6rnbrack,\u00a0Adrian\u00a0Tasso ni,\u00a0Sabine\u00a0Stein,\u00a0Sibylle\u00a0Vogt,\u00a0\nDaniela\u00a0Z\u00f6ller,\u00a0G\u00fcnther\u00a0Bernert,\u00a0Tim\u00a0Hagenacker,\u00a0Ulrike\u00a0Schara\u2010Schmidt,\u00a0Inge\u00a0Schwersenz ,\u00a0Maggie\u00a0C\u00a0\nWalter,\u00a0Matthias\u00a0Baumann ,\u00a0Manuela\u00a0Baumgartner ,\u00a0Marcus\u00a0Deschauer ,\u00a0Astrid\u00a0Eisenk\u00f6lbl ,\u00a0Marina\u00a03Flotats\u2010Bastardas ,\u00a0Andreas\u00a0Hahn ,\u00a0Veronka\u00a0Horber ,\u00a0Ralf\u00a0A\u00a0Husain ,\u00a0Sabine\u00a0Illsinger ,\u00a0Jessika\u00a0Johannsen ,\u00a0\nCornelia\u00a0K\u00f6hler ,\u00a0Heike\u00a0K\u00f6lbel ,\u00a0Monika\u00a0M\u00fcller ,\u00a0Arpad\u00a0von\u00a0Moers ,\u00a0Kurt\u00a0Schlachter ,\u00a0Gudrun\u00a0Schreiber ,\u00a0\nOliver\u00a0Schwartz ,\u00a0Martin\u00a0Smitka ,\u00a0Elisabeth\u00a0Steiner ,\u00a0Eva\u00a0St\u00f6gmann ,\u00a0Regina\u00a0Trollmann ,\u00a0Katharina\u00a0Vill ,\u00a0\nClaudia\u00a0Wei\u00df ,\u00a0Gert\u00a0Wiegand ,\u00a0Andreas\u00a0Ziegler ,\u00a0Hanns\u00a0Lochm\u00fcller ,\u00a0Janbernd\u00a0Kirschner ,\u00a0the\u00a0SMArtCARE\u00a0\nstudy\u00a0group\u00a0\nBrain,\u00a0awac252,\u00a0https://doi.org/10.1093/brain/awac252\u00a0\n\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://academic.oup.com/brain/advance\u2010\narticle/doi/10.1093/brain /awac252/6647488?login=true \u00a0 \n\u00a0\n\u00a0\nImproved\u00a0upper\u00a0limb\u00a0function\u00a0in\u00a0non\u2010ambulant\u00a0children\u00a0with\u00a0SMA\u00a0 type\u00a02\u00a0and\u00a03\u00a0during\u00a0\nnusinersen\u00a0treatment:\u00a0a\u00a0prospecti ve\u00a03\u2010years\u00a0SMArtCARE\u00a0registry\u00a0 study\u00a0\nAstrid\u00a0Pechmann,\u00a0Max\u00a0Behrens,\u00a0Ka tharina\u00a0D\u00f6rnbrack,\u00a0Adrian\u00a0Tasso ni,\u00a0Franziska\u00a0Wenzel,\u00a0Sabine\u00a0Stein,\u00a0\nSibylle\u00a0Vogt,\u00a0Daniela\u00a0Z\u00f6ller,\u00a0G\u00fcn ther\u00a0Bernert,\u00a0Tim\u00a0Hagenacker,\u00a0 Ulrike\u00a0Schara\u2010Schmidt,\u00a0Maggie\u00a0C.\u00a0Walter,\u00a0\nAstrid\u00a0Bertsche,\u00a0Katharina\u00a0Vill,\u00a0M atthias\u00a0Baumann,\u00a0Manuela\u00a0Baum gartner,\u00a0Isabell\u00a0Cordts,\u00a0Astrid\u00a0\nEisenk\u00f6lbl,\u00a0Marina\u00a0Flotats\u2010Basta rdas,\u00a0Johannes\u00a0Friese,\u00a0Ren\u00e9\u00a0G\u00fcn ther,\u00a0Andreas\u00a0Hahn,\u00a0Veronka\u00a0Horber,\u00a0Ralf\u00a0\nA.\u00a0Husain,\u00a0Sabine\u00a0Illsinger,\u00a0J\u00f6rg\u00a0Jahnel,\u00a0Jessika\u00a0Johannsen,\u00a0Co rnelia\u00a0K\u00f6hler,\u00a0Heike\u00a0K\u00f6lbel,\u00a0Monika\u00a0M\u00fcller,\u00a0\nArpad\u00a0von\u00a0Moers,\u00a0Annette\u00a0Schwerin \u2010Nagel,\u00a0Christof\u00a0Reihle,\u00a0Kurt\u00a0 Schlachter,\u00a0Gudrun\u00a0Schreiber,\u00a0Oliver\u00a0\nSchwartz,\u00a0Martin\u00a0Smitka,\u00a0Elisab eth\u00a0Steiner,\u00a0Regina\u00a0Trollmann,\u00a0M arkus\u00a0Weiler,\u00a0Claudia\u00a0Wei\u00df,\u00a0Gert\u00a0\nWiegand,\u00a0Ekkehard\u00a0Wilichowski,\u00a0Andreas\u00a0Ziegler,\u00a0Hanns\u00a0Lochm\u00fclle r,\u00a0Janbernd\u00a0Kirschner\u00a0&\u00a0SMArtCARE\u00a0\nstudy\u00a0group.\u00a0Orphanet\u00a0Journal\u00a0of \u00a0Rare\u00a0Diseases\u00a0volume\u00a017,\u00a0Artic le\u00a0number:\u00a0384\u00a0(2022)\u00a0\n\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://ojrd.b iomedcentral.com/articles/10.11 86/s13023\u2010022\u201002547\u20108\u00a0\n\u00a0\n\u00a0\nPatientenpartizipation\u00a0in\u00a0der\u00a0p\u00e4diatrischen\u00a0Versorgungsforschun g\u00a0am\u00a0Universit\u00e4tsklinikum\u00a0\nFreiburg:\u00a0von\u00a0der\u00a0Projektbete iligung\u00a0zum\u00a0Patientenbeirat\u00a0\nLanger\u00a0T,\u00a0Gusset\u00a0N,\u00a0Pechmann\u00a0A, \u00a0Stumpe\u00a0E,\u00a0D\u00fcrr\u00a0S,\u00a0Mund\u00a0A,\u00a0Matil ainen\u00a0J,\u00a0Meyer\u00a0S,\u00a0Barth\u00a0M,\u00a0Haddad\u00a0A.\u00a0\nZ\u00a0Evid\u00a0Fortbild\u00a0Qual\u00a0Gesundhw es.\u00a02022\u00a0Sep;173:98\u2010105.\u00a0German.\u00a0d oi:\u00a010.1016/j.zefq.2022.07.002.\u00a0\nEpub\u00a02022\u00a0Aug\u00a0 26.\u00a0PMID:\u00a036038462. \u00a0\n\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/36038462/ \u00a0\nAusf\u00fchrlich:\u00a0s.\u00a0unten\u00a0\n\u00a0\n\u00a0\nGenotype\u2010phenotype\u00a0asso ciations\u00a0within\u00a0the\u00a0Li\u2010Fraumeni\u00a0spectrum :\u00a0a\u00a0report\u00a0from\u00a0the\u00a0\nGerman\u00a0Registry \u00a0\nJudith\u00a0Penkert,\u00a0Farina\u00a0J\u00a0Str\u00fcwe, \u00a0Christina\u00a0M\u00a0Dutzmann,\u00a0Beate\u00a0B\u00a0 Doergeloh,\u00a0Emilie\u00a0Montellier,\u00a0Claire\u00a0\nFreycon,\u00a0Myriam\u00a0Keymling,\u00a0Heinz\u2010Peter\u00a0Schlemmer,\u00a0Birte\u00a0S\u00e4nger,\u00a0 Beatrice\u00a0Hoffmann,\u00a0Tanja\u00a0\nGerasimov,\u00a0Claudia\u00a0Blattmann,\u00a0Sebastian\u00a0Fetscher,\u00a0Michael\u00a0Fr\u00fchw ald,\u00a0Simone\u00a0Hettmer,\u00a0Uwe\u00a0Kordes,\u00a0\nVita\u00a0Ridola,\u00a0Sabine\u00a0Kroiss\u00a0Benninger,\u00a0Angela\u00a0Mastronuzzi,\u00a0Sarah \u00a0Schott,\u00a0Juliane\u00a0Nees,\u00a0Aram\u00a0Prokop,\u00a0\nAntje\u00a0Redlich,\u00a0Markus\u00a0G\u00a0Seidel,\u00a0 Stefanie\u00a0Zimmermann,\u00a0Kristian\u00a0W \u00a0Pajtler,\u00a0Stefan\u00a0M\u00a0Pfister,\u00a0Pierre\u00a0\nHainaut,\u00a0Christian\u00a0P\u00a0Kratz,\u00a0J\u00a0 Hematol\u00a0Oncol.2022\u00a0Aug\u00a016;15(1):1 07.\u00a0doi:\u00a010.1186/s13045\u2010022\u201001332\u20101.\u00a0\n\u00a0\nLink\u00a0zum\u00a0Artikel:\u00a0https://pubmed .ncbi.nlm.nih.gov/35974385/ \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a04\u00dcbersicht\u00a0der\u00a0n\u00e4chsten\u00a0Fortbildungen\u00a0f\u00fcr\u00a0Studienmitarbeiter\u00a0\nam\u00a0Zentrum\u00a0Klinische\u00a0Studien\u00a0(ZKS) \u00a0\n \nGrundlagen\u2010\u00a0und\u00a0Aufbaukurs\u00a0\n(fr\u00fcher\u00a0Pr\u00fcferkurs)\u00a0\u00a007.12.2022\u00a0(Grundlagenkurs)\u00a0\n08.12.2022\u00a0(Aufbaukurs)\u00a0\n08.02.2023\u00a0(Grundlagenkurs)\u00a0\n09.02.2023\u00a0(Aufbaukurs)\u00a0\nUpdate\u2010Kurs\u00a0GCP\u00a0(neue\u00a0EU\u2010\nVerordnung)\u00a0 \n\u00a0\n14.03.2023\u00a0\nAuf\u00a0Nachfrage\u00a0wird\u00a0der\u00a0Kurs\u00a0auch\u00a0zus\u00e4tzlich\u00a0ab\u00a05\u00a0\nTeilnehmern\u00a0angeboten.\u00a0\n\u00a0\nKombinierter\u00a0Grundlagen\u2010\u00a0\nund\u00a0Aufbauerg\u00e4nzungskurs\u00a0\nMPG\u00a0\n\u00a0\nVerantwortlichkeiten\u00a0eines\u00a0\nStudienleiters\u00a0(IIT)\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a015.11.2022\u00a0\u00a0\n26.01.2023\u00a0\n\u00a0\n29./30.11.2022\u00a0\u00a0\n23./24.05.2023\u00a0\u00a0\n\u00a0\n\u00a0\nWeitere\u00a0Informationen\u00a0unter:\u00a0h ttps://www.uniklinik\u2010freiburg.de/ zks/fortbildungen.html \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nNeu\u00a0begonnene\u00a0Studien\u00a0am\u00a0ZKJ\u00a0\u00a0\n\u00a0\nAllgemeine\u00a0Kinder\u2010\u00a0und\u00a0Jugendmedizin \u00a0\n\u00a0\nDTX401\u2010CL301:\u00a0A\u00a0Phase\u00a03\u00a0Randomize d,\u00a0Double\u2010Blind,\u00a0Placebo\u2010Contr olled\u00a0Study\u00a0of\u00a0Adeno\u2010\nAssociated\u00a0Virus\u00a0Serotype\u00a08\u2010Medi ated\u00a0Gene\u00a0Transfer\u00a0of\u00a0Glucose\u20106 \u2010Phosphatase\u00a0in\u00a0Patients\u00a0\nwith\u00a0Glycogen\u00a0Storage\u00a0Di sease\u00a0Type\u00a0Ia,\u00a0Ph.\u00a0III\u00a0\n\u00a0\nGlykogenspeicherkrankheit\u00a0Typ\u00a0Ia,\u00a0Kinder\u00a0und\u00a0Erwachsene\u00a0ab\u00a08\u00a0Ja hren,\u00a0aktiv\u00a0seit\u00a028.09.22\u00a0\n \nWeitere\u00a0Informationen:\u00a0www.c linicaltrials.gov:\u00a0NCT05139316 \u00a0\nAusf\u00fchrlich:\u00a0s.\u00a0unten\u00a0\n\u00a0\n\u00a0\nPediatric\u00a0Airway\u00a0Pathogen\u00a0Inciden ce\u00a0(PAPI\u00a03.0),\u00a0Epidemiologisch e\u00a0Studie\u00a0\n\u00a0\nRSV\u2010Infektionen\u00a0mit\u00a0Hospitalisation,\u00a00\u20102\u00a0Jahre,\u00a0aktiv\u00a0seit\u00a009/2 022\u00a0\n\u00a0\n\u00a05Neurop\u00e4diatrie\u00a0und\u00a0Muskelerkrankungen\u00a0\nNEOS\u00a0\u2013\u00a0CBAF312D2301:\u00a0Phase\u00a0III\u2010Studie\u00a0zur\u00a0Untersuchung\u00a0der\u00a0Wirk samkeit\u00a0und\u00a0Sicherheit\u00a0\nvon\u00a0Ofatumumab\u00a0und\u00a0Siponimod\u00a0im\u00a0Vergleich\u00a0zu\u00a0Fingolimod\u00a0bei\u00a0p\u00e4diatrischen\u00a0Patienten\u00a0\nmit\u00a0Multipler\u00a0Sklerose\u00a0\nMultiple\u00a0Sklerose\u00a0(MS),\u00a0Kinder\u00a0 und\u00a0Jugendliche\u00a0im\u00a0Alter\u00a0von\u00a010\u2010 17\u00a0Jahre,\u00a0aktiv\u00a0seit\u00a011/2022\u00a0\nWeitere\u00a0Informationen:\u00a0www.c linicaltrials.gov:\u00a0NCT04926818  \nAngeborene\u00a0Herzfehler/P\u00e4diatrische\u00a0Kardiologie \u00a0\nMK\u20101654\u2010007:\u00a0Eine\u00a0multizentrische,\u00a0randomisierte,\u00a0teilverblinde te,\u00a0Pavilizumab\u2010\nkontrollierte\u00a0Phase\u00a0\u20103\u2010Studie\u00a0zu r\u00a0Beurteilung\u00a0der\u00a0Sicherheit,\u00a0Wirksamkeit\u00a0und\u00a0\nPharmakokinetik\u00a0von\u00a0MK\u20101654\u00a0bei\u00a0 S\u00e4uglingen\u00a0und\u00a0Kindern\u00a0mit\u00a0erh\u00f6 htem\u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0\nschwere\u00a0RSV\u2010Infektion \u00a0\nRSV\u2010Immunisierung\u00a0bei\u00a0S\u00e4uglingen\u00a0mit\u00a0erh\u00f6htem\u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0s chwere\u00a0RSV\u2010Infektion\u00a0\n(Fr\u00fchgeburt,\u00a0Angeborene\u00a0Herzfehl er\u00a0&\u00a0chronische\u00a0Lungenkrankheit ),\u00a00\u20102\u00a0Jahre,\u00a0aktiv\u00a0seit\u00a0\n10/2022\u00a0\nWeitere\u00a0Informationen:\u00a0www.clinicaltrials.gov:\u00a0NCT04938830\u00a0\nAusf\u00fchrlich:\u00a0s.\u00a0unten\u00a0\nRegiVe\u00a0Study:\u00a0Registry\u00a0to\u00a0asse ss\u00a0the\u00a0Safety\u00a0and\u00a0Feasibility\u00a0of\u00a0 the\u00a0Subpulmonary\u00a0Support\u00a0\nwith\u00a0the\u00a0novel\u00a0Venous\u00a0Cannula\u00a0in \u00a0Patients\u00a0with\u00a0Failing/Absence\u00a0of\u00a0the\u00a0Right\u00a0Heart,\u00a0Sonstige\u00a0\nStudie\u00a0(\u00a7\u00a023b\u00a0MPG) \u00a0\nPatient*innen\u00a0mit\u00a0terminaler\u00a0Rechtsherzinsuffizienz/fehlendem\u00a0r echten\u00a0Ventrikel\u00a0im\u00a0\nZusammenhang\u00a0mit\u00a0einer\u00a0ventrikul\u00e4ren\u00a0Herzunterst\u00fctzungssystem\u00a0( VAD),\u00a00\u201099\u00a0Jahre,\u00a0aktiv\u00a0\nseit\u00a010/2022\u00a0\nWeitere\u00a0Informationen:\u00a0www.clinicaltrials.gov:\u00a0NCT04782232\u00a0\nP\u00e4diatrische\u00a0H\u00e4matologie\u00a0und\u00a0Onkologie \u00a0\nALL\u00a0SCT\u00a0FORUM\u00a0Registry\u00a02022:\u00a0Allogene\u00a0Stammzelltransplantation\u00a0 bei\u00a0Kindern\u00a0und\u00a0\nJugendlichen\u00a0mit\u00a0Akuter\u00a0Lymphatischer\u00a0Leuk\u00e4mie,\u00a0Register \u00a0\nAllogene\u00a0Stammzelltransplantation\u00a0bei\u00a0Patienten\u00a0mit\u00a0ALL\u00a0in\u00a0Remi ssion\u00a0mit\u00a0hohem\u00a0Risiko\u00a0oder\u00a0\nsehr\u00a0hohem\u00a0Risiko\u00a0eines\u00a0Rezidivs, \u00a00\u00a0bis\u00a0<\u00a021\u00a0Jahre,\u00a0aktiv\u00a0seit\u00a0 13.09.2022\u00a0\nTRACE:\u00a0Therapie\u00a0refrakt\u00e4rer\u00a0Virusinfektionen\u00a0nach\u00a0allogener\u00a0Sta mmzelltransplantation\u00a0mit\u00a0\nmultispezifischen\u00a0T\u2010Zellen\u00a0gegen\u00a0CMV,\u00a0EBV\u00a0und\u00a0AdV:\u00a0Eine\u00a0prospek tive,\u00a0multizentrische\u00a0\nklinische\u00a0Studie\u00a0der\u00a0Phase\u00a0III\u00a06Refrakt\u00e4re\u00a0Virusinfektionen\u00a0nach \u00a0allogener\u00a0Stammzelltransplanta tion\u00a0mit\u00a0multispezifischen\u00a0T\u2010\nZellen\u00a0gegen\u00a0CMV,\u00a0EBV\u00a0und\u00a0AdV,\u00a0a b\u00a02\u00a0Monaten,\u00a0aktiv\u00a0seit\u00a003.11.2 022\u00a0\n\u00a0\nWeitere\u00a0Informationen:\u00a0drks.de:\u00a0DRKS00018985 \u00a0\n\u00a0\nLink\u00a0zur\u00a0Homepage \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nAusf\u00fchrlich\u00a0beleuchtet\u00a0\nDTX401\u2010CL301: \tA\u00a0Study\u00a0of\u00a0Adeno\u2010Associated\u00a0Virus \u00a0Serotype\u00a08\u2010Mediated\u00a0Gene\u00a0Tran sfer\u00a0of\u00a0\nGlucose\u20106\u2010Phosphatase\u00a0in\u00a0Patients \u00a0With\u00a0Glycogen\u00a0Storage\u00a0Disease \u00a0Type\u00a0Ia\u00a0(GSDIa),\u00a0EudraCT\u2010\nNummer:\u00a02020\u2010004184\u201012\u00a0\n \nDie\u00a0Glykogenose\u00a0Typ\u00a0Ia\u00a0(GSD\u00a0Ia)\u00a0 ist\u00a0eine\u00a0sehr\u00a0seltene\u00a0genetisch e\u00a0Stoffwechselst\u00f6rung\u00a0des\u00a0\nKohlenhydratstoffwechsels,\u00a0die\u00a0a uf\u00a0einem\u00a0Mangel\u00a0des\u00a0Enzyms\u00a0Gluc ose\u20106\u2010Phosphatase\u00a0beruht.\u00a0\nBei\u00a0Patienten\u00a0mit\u00a0dieser\u00a0Stoffwechselerkrankung\u00a0ist\u00a0in\u00a0N\u00fcchtern phasen\u00a0sowohl\u00a0die\u00a0\nGlykogenolyse\u00a0als\u00a0auch\u00a0die\u00a0Gluconeogenese\u00a0gest\u00f6rt.\u00a0Daher\u00a0besteh t\u00a0ein\u00a0sehr\u00a0hohes\u00a0Risiko\u00a0f\u00fcr\u00a0\nUnterzuckerungen,\u00a0und\u00a0die\u00a0Fastento leranz\u00a0betr\u00e4gt\u00a0in\u00a0der\u00a0Regel\u00a0n ur\u00a0ca.\u00a03\u20104\u00a0Stunden.\u00a0Zudem\u00a0\nzeigt\u00a0sich\u00a0typischerweise\u00a0eine\u00a0Lebervergr\u00f6\u00dferung\u00a0sowie\u00a0ein\u00a0Klei nwuchs.\u00a0Die\u00a0Behandlung\u00a0\nerfordert\u00a0eine\u00a0lebenslange\u00a0Spezi aldi\u00e4t.\u00a0Nachts\u00a0ist\u00a0entweder\u00a0ein e\u00a0n\u00e4chtliche\u00a0Dauersondierung\u00a0\n\u00fcber\u00a0eine\u00a0Magensonde/PEG\u2010Sonde\u00a0ode r\u00a0die\u00a0Einnahme\u00a0ungekochter\u00a0Ma isst\u00e4rke\u00a0in\u00a0\nregelm\u00e4\u00dfigen\u00a0Abst\u00e4nden\u00a0zur\u00a0Stabilisierung\u00a0des\u00a0Blutzuckers\u00a0erfor derlich.\u00a0\u00a0\nBereits\u00a0seit\u00a0vielen\u00a0Jahren\u00a0wird\u00a0an \u00a0einer\u00a0Gentherapie\u00a0f\u00fcr\u00a0die\u00a0GS D\u00a0Ia\u00a0geforscht.\u00a0Die\u00a0Phase\u00a0I/II\u2010\nStudien,\u00a0in\u00a0denen\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0bei\u00a0insgesamt\u00a0 12\u00a0erwachsenen\u00a0Patienten\u00a0\nuntersucht\u00a0wurden,\u00a0sind\u00a0bereits\u00a0a bgeschlossen.\u00a0Vor\u00a0Kurzem\u00a0start ete\u00a0die\u00a0internationale\u00a0Phase\u00a0\nIII\u2010Studie\u00a0DTX401\u2010CL301\u00a0des\u00a0Sponsor s\u00a0Ultragenyx,\u00a0an\u00a0der\u00a0auch\u00a0da s\u00a0Stoffwechselzentrum\u00a0\nFreiburg\u00a0als\u00a0eines\u00a0von\u00a02\u00a0deutschen\u00a0Studienzentren\u00a0beteiligt\u00a0ist .\u00a0Die\u00a0Studie\u00a0ist\u00a0eine\u00a0\ninternationale\u00a0Studie\u00a0mit\u00a0mehr\u00a0a ls\u00a020\u00a0Studienzentren\u00a0weltweit.\u00a0 Geplant\u00a0ist\u00a0der\u00a0Einschluss\u00a0von\u00a0\ninsgesamt\u00a050\u00a0Patienten,\u00a0davon\u00a010\u00a0Kindern\u00a0\u00fcber\u00a08\u00a0Jahre.\u00a0\nDie\u00a0Studie\u00a0wird\u00a0als\u00a0placebo\u2010kontrollierte\u00a0Doppelblindstudie\u00a0mit \u00a0einem\u00a0Cross\u2010over\u2010Design\u00a0\ndurchgef\u00fchrt.\u00a0Die\u00a0Gentherapie\u00a0erf olgt\u00a0als\u00a0einmalige\u00a0Infusion.\u00a0H ierbei\u00a0wird\u00a0das\u00a0gesunde\u00a0Gen\u00a0\nmittels\u00a0eines\u00a0nicht\u00a0pathogenen\u00a0Vi rus\u2010Vektors,\u00a0eines\u00a0AAV8\u2010Vektor s,\u00a0in\u00a0die\u00a0Leber\u00a0eingebracht.\u00a0\nUntersucht\u00a0wird,\u00a0ob\u00a0sich\u00a0hierdur ch\u00a0zum\u00a0einen\u00a0die\u00a0N\u00fcchterntolera nz\u00a0erh\u00f6ht\u00a0und\u00a0ob\u00a0der\u00a0Bedarf\u00a0\nan\u00a0Maisst\u00e4rke\u00a0zur\u00a0Stabilisierung\u00a0des\u00a0Blutzuckers\u00a0abnimmt.\u00a0Um\u00a0di es\u00a0beurteilen\u00a0zu\u00a0k\u00f6nnen,\u00a0wird\u00a0\ndie\u00a0Di\u00e4t\u00a0sehr\u00a0genau\u00a0protokolliert,\u00a0und\u00a0es\u00a0werden\u00a0regelm\u00e4\u00dfige\u00a0ko ntrollierte\u00a0Fastentests\u00a0\ndurchgef\u00fchrt.\u00a0\u00a0\nIn\u00a0Freiburg\u00a0k\u00f6nnen\u00a0voraussichtlich\u00a0zwei\u00a0GSD\u00a0Ia\u2010Patienten\u00a0in\u00a0die \u00a0Studie\u00a0eingeschlossen\u00a0werden,\u00a0\nund\u00a0die\u00a0Rekrutierung\u00a0soll\u00a0noch\u00a0in\u00a0 diesem\u00a0Jahr\u00a0abgeschlossen\u00a0wer den.\u00a0\nAnsprechpartner\u00a0am\u00a0ZKJ:\u00a0Prof.\u00a0Dr.\u00a0Sarah\u00a0Gr\u00fcnert\u00a0\n\u00a0\nWeitere\u00a0Informationen:\u00a0www.c linicaltrials.gov:\u00a0NCT05139316\u00a0\n\u00a0\n\u00a0\nMK\u20101654\u2010007:\u00a0Eine\u00a0multizentrisc he,\u00a0randomisierte,\u00a0teilverblinde te,\u00a0Pavilizumab\u2010\nkontrollierte\u00a0Phase\u00a0\u20103\u2010Studie\u00a0zu r\u00a0Beurteilung\u00a0der\u00a0Sicherheit,\u00a0W irksamkeit\u00a0und\u00a07Pharmakokinetik\u00a0von\u00a0MK\u20101654\u00a0bei\u00a0 S\u00e4uglingen\u00a0und\u00a0Kindern\u00a0mit\u00a0erh\u00f6 htem\u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0\nschwere\u00a0RSV\u2010Infektion\u00a0\n\u00a0\nMK\u20101654\u00a0(Clesrovimab)\u00a0 ist\u00a0ein\u00a0monoklonaler\u00a0anti\u2010RSV\u2010Antik\u00f6rper\u00a0 (mAk),\u00a0der\u00a0entwickelt\u00a0wurde,\u00a0\num\u00a0RSV\u2010Virus\u00a0bedingte\u00a0Pneumonien\u00a0im\u00a0S\u00e4uglingsalter\u00a0vorzubeugen. \u00a0\nMK\u20101654\u00a0ist\u00a0gegen\u00a0das\u00a0RSV\u2010F\u2010Prot ein\u00a0gerichtet.\u00a0RSV\u2010F\u00a0wird\u00a0vom\u00a0V irus\u00a0genutzt,\u00a0um\u00a0in\u00a0Wirtszellen\u00a0\neinzudringen\u00a0und\u00a0infizierte\u00a0Zellen\u00a0mit\u00a0benachbarten\u00a0Zellen\u00a0zu\u00a0v erschmelzen,\u00a0sodass\u00a0es\u00a0sich\u00a0\ndurch\u00a0die\u00a0Bildung\u00a0von\u00a0Synzytien\u00a0verbreiten\u00a0kann.\u00a0MK\u20101654\u00a0bedarf \u00a0lediglich\u00a0einer\u00a0einmaligen\u00a0\nInjektion\u00a0pro\u00a0RSV\u2010Saison.\u00a0Diese\u00a0Studie\u00a0wurde\u00a0im\u00a0Jahr\u00a02021\u00a0durch \u00a0den\u00a0Sponsor\u00a0MSD\u00a0Sharp\u00a0&\u00a0\nDohme\u00a0GmbH\u00a0initiiert.\u00a0\nUnser\u00a0Pr\u00fcfzentrum\u00a0wurde\u00a0im\u00a0\u201eSchnellverfahren\u201c\u00a0durch\u00a0den\u00a0Sponsor \u00a0nachvalidiert\u00a0und\u00a0ist\u00a0seit\u00a0\n10/2022\u00a0f\u00fcr\u00a0die\u00a0Rekrutierung\u00a0freigegeben.\u00a0S\u00e4uglinge\u00a0mit\u00a0therapi ebed\u00fcrftigen\u00a0angeborenen\u00a0\nHerzfehlern\u00a0besitzen\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0einen\u00a0schweren\u00a0Ver lauf\u00a0bei\u00a0einer\u00a0RSV\u2010Infektion.\u00a0\nUnsere\u00a0Rekrutierung\u00a0fokussiert\u00a0sich\u00a0auf\u00a0S\u00e4uglinge\u00a0mit\u00a0komplexen \u00a0angeborenen\u00a0Herzfehlern.\u00a0\nDiese\u00a0Studie\u00a0ist\u00a0randomisiert,\u00a0teilverblindet\u00a0und\u00a0durch\u00a0Paliviz umab\u00a0(Synagis\u00ae)\u00a0kontrolliert.\u00a0Die\u00a0\nMK\u20101654\u2010Gruppe\u00a0erh\u00e4lt\u00a0den\u00a0monoklonalen\u00a0Antik\u00f6rper\u00a0und\u00a0am\u00a028.\u00a0Ta g\u00a0eine\u00a0Placeboinjektion\u00a0\n(NaCl\u00a00,9%).\u00a0Die\u00a0Kontrollgruppe\u00a0erh\u00e4lt\u00a0alle\u00a028\u00a0Tage\u00a0Pavilizumab .\u00a0Am\u00a060.\u00a0Tag\u00a0wird\u00a0entblindet,\u00a0\ndamit\u00a0 den\u00a0 Kindern\u00a0 der\u00a0 MK\u20101654\u2010Gruppe\u00a0 weitere\u00a0 Injektionen\u00a0 erspar t\u00a0 bleiben.\u00a0 Die\u00a0\nKontrollgruppe\u00a0erh\u00e4lt\u00a0bis\u00a0zum\u00a0Ende \u00a0der\u00a0RSV\u2010Saison\u00a01\u00a0regelm\u00e4\u00dfig\u00a0 (alle\u00a028.\u00a0Tage)\u00a0Pavilizumab.\u00a0In\u00a0\nder\u00a0gesamten\u00a0Nachbeobachtungszei t\u00a0(180\u00a0Tage)\u00a0wird\u00a0ein\u00a0w\u00f6chentli cher\u00a0Telefonkontakt\u00a0zu\u00a0den\u00a0\nEltern/gesetzlichen\u00a0Vertreter*i nnen\u00a0durch\u00a0unser\u00a0Pr\u00fcfzentrum\u00a0for tgef\u00fchrt.\u00a0Dieser\u00a0wird\u00a0begleitet\u00a0\ndurch\u00a0digitale\u00a0Tagebucheintr\u00e4ge,\u00a0welche\u00a0die\u00a0Eltern\u00a0\u00fcber\u00a0ein\u00a0Stu dien\u2010Smartphone\u00a0eingeben\u00a0\nk\u00f6nnen.\u00a0\u00a0\nBei\u00a0erfolgreicher\u00a0Teilnahme\u00a0in\u00a0der\u00a0ersten\u00a0RSV\u2010Saison\u00a0haben\u00a0die\u00a0 Teilnehmenden\u00a0die\u00a0M\u00f6glichkeit,\u00a0\nim\u00a0folgenden\u00a0Jahr\u00a0erneut\u00a0teilzunehmen.\u00a0Hierbei\u00a0wird\u00a0jedem/r\u00a0Tei lnehmenden\u00a0das\u00a0Pr\u00fcfpr\u00e4parat\u00a0\nMK\u20101654\u00a0verabreicht,\u00a0wodurch\u00a0die \u00a0S\u00e4uglinge\u00a0nur\u00a0eine\u00a0einzige\u00a0Inj ektion\u00a0erhalten\u00a0m\u00fcssen.\u00a0\nAnsprechpartner\u00a0am\u00a0ZKJ:\u00a0Prof.\u00a0Dr .\u00a0B.\u00a0Stiller,\u00a0PD\u00a0Dr.\u00a0R.\u00a0Kubicki ,\u00a0Nicolas\u00a0Enriquez\u00a0(B.A)\u00a0\n\u00a0\nWeitere\u00a0Informationen:\u00a0www.clin icaltrials.gov:\u00a0NCT04938830\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nDer\u00a0Patient*innenbeirat\u00a0in\u00a0der\u00a0 Versorgungsforschung\u00a0\u2013\u00a0Blick\u00a0zur \u00fcck\u00a0und\u00a0\nnach\u00a0vorn\u00a0\n\u00a0\n\u00a0\n\u00a0\nVor\u00a0zwei\u00a0Jahren\u00a0wurde\u00a0der\u00a0Patien t*innenbeirat\u00a0der\u00a0AG\u00a0Versorgung sforschung\u00a0am\u00a0ZKJ\u00a0\ngegr\u00fcndet.\u00a0Durch\u00a0die\u00a0regelm\u00e4\u00dfige \u00a0Beteiligung\u00a0von\u00a0Patient*innen, \u00a0Angeh\u00f6rigen\u00a0und\u00a0\nPatientenvertreter*innen\u00a0sollten \u00a0gewisserma\u00dfen\u00a0systematisch\u00a0Gel egenheiten\u00a0entstehen,\u00a0dass\u00a0\nBetroffene\u00a0ihr\u00a0Erfahrungswisse n\u00a0einbringen\u00a0und\u00a0den\u00a0Forschungspr ozess\u00a0mitgestalten\u00a0k\u00f6nnen.\u00a0\nDabei\u00a0werden\u00a0mehrere\u00a0Ziele\u00a0verfo lgt.\u00a0Zun\u00e4chst\u00a0soll\u00a0der\u00a0Beirat\u00a0m ithelfen,\u00a0dass\u00a0die\u00a0Forschung\u00a0\neine\u00a0hohe\u00a0Relevanz\u00a0f\u00fcr\u00a0Betroffene \u00a0hat.\u00a0Das\u00a0geschieht\u00a0dadurch,\u00a0d ass\u00a0im\u00a0Beirat\u00a0Forschende\u00a0und\u00a0\nPatientenvertreter*innen\u00a0gemeins am\u00a0Themen\u00a0diskutieren\u00a0und\u00a0Forsc hungsfragen\u00a0entwickeln.\u00a0\u00a0\nDes\u00a0Weiteren\u00a0soll\u00a0die\u00a0Durchf\u00fchr ung\u00a0der\u00a0Forschung\u00a0m\u00f6glichst\u00a0pati ent*innen\u2010\u00a0und\u00a0\nfamilienzentriert\u00a0realisiert\u00a0werden.\u00a0Das\u00a0zeigt\u00a0sich\u00a0zum\u00a0Beispie l\u00a0darin,\u00a0welchen\u00a0Umfang\u00a0\nFrageb\u00f6gen\u00a0haben,\u00a0die\u00a0Betroffene\u00a0ausf\u00fcllen\u00a0sollen.\u00a0Sind\u00a0Frageb\u00f6 gen\u00a0zu\u00a0lang,\u00a0werden\u00a0sie\u00a0\nentweder\u00a0unvollst\u00e4ndig\u00a0oder\u00a0mit\u00a0geringerer\u00a0Aufmerksamkeit\u00a0ausge f\u00fcllt,\u00a0was\u00a0wiederum\u00a0die\u00a0\nQualit\u00e4t\u00a0der\u00a0Ergebnisse\u00a0beeintr\u00e4chtigt.\u00a0Au\u00dferdem\u00a0ist\u00a0die\u00a0Beteil igung\u00a0wertvoll\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0\nInterpretation\u00a0von\u00a0Ergebnissen,\u00a0d ie\u00a0je\u00a0nach\u00a0Perspektive\u00a0zwische n\u00a0Forschenden\u00a0und\u00a0\nBetroffenen\u00a0variieren\u00a0kann.\u00a0\u00a0\n8Trotz\u00a0der\u00a0genannten\u00a0Vorteile\u00a0ein er\u00a0Patient*innenbeteiligung\u00a0an\u00a0 der\u00a0Forschung\u00a0sind\u00a0in\u00a0\nDeutschland\u00a0die\u00a0Erfahrungen\u00a0in\u00a0d er\u00a0partizipativen\u00a0Forschung,\u00a0in sbesondere\u00a0in\u00a0der\u00a0P\u00e4diatrie,\u00a0\n\u00fcberschaubar.\u00a0Die\u00a0vergangenen\u00a0zwei\u00a0Jahren\u00a0waren\u00a0daher\u00a0f\u00fcr\u00a0Forsc hende\u00a0und\u00a0Teilnehmende\u00a0\ndes\u00a0Beirats\u00a0sehr\u00a0lehrreich.\u00a0Die\u00a0b isherigen\u00a0Erfahrungen\u00a0konnten\u00a0 in\u00a0der\u00a0Schwerpunktereihe\u00a0der\u00a0\nZeitschrift\u00a0f\u00fcr\u00a0Evidenz,\u00a0Fortbildung\u00a0und\u00a0Qualit\u00e4t\u00a0im\u00a0Gesundheit swesen\u00a0(ZEFQ)\u00a0ver\u00f6ffentlicht\u00a0\nwerden.\u00a0Als\u00a0wesentlich\u00a0f\u00fcr\u00a0die\u00a0erfolgreiche\u00a0Zusammenarbeit\u00a0habe n\u00a0sich\u00a0zwei\u00a0Aspekte\u00a0\nherauskristallisiert:\u00a0Erstens,\u00a0die \u00a0Arbeit\u00a0an\u00a0gemeinsamen\u00a0Themen \u00a0und\u00a0Inhalten\u00a0ist\u00a0wichtiger\u00a0als\u00a0\ngekl\u00e4rte\u00a0Strukturen\u00a0im\u00a0Verh\u00e4ltni s\u00a0zwischen\u00a0Forschenden\u00a0und\u00a0Pati entenvertreter*innen.\u00a0\nZweitens,\u00a0eine\u00a0kontinuierliche\u00a0Ref lexion\u00a0\u00fcber\u00a0den\u00a0gemeinsamen\u00a0A rbeitsprozess\u00a0in\u00a0der\u00a0fr\u00fchen\u00a0\nEntwicklungsphase\u00a0ist\u00a0wichtig,\u00a0um\u00a0die\u00a0jeweiligen\u00a0Erwartungen\u00a0un d\u00a0M\u00f6glichkeiten\u00a0transparent\u00a0\nzu\u00a0machen\u00a0und\u00a0gemeinsame\u00a0Ziele\u00a0f ormulieren\u00a0zu\u00a0k\u00f6nnen.\u00a0Die\u00a0Zusam menarbeit\u00a0mit\u00a0einer\u00a0\nexternen\u00a0Moderatorin\u00a0war\u00a0sehr\u00a0hilfreich.\u00a0\nIn\u00a0diesem\u00a0Sinne\u00a0hat\u00a0der\u00a0Patient*i nnenbeirat\u00a0in\u00a0seinem\u00a0letzten\u00a0T reffen\u00a0diskutiert\u00a0und\u00a0\nentschieden,\u00a0seinen\u00a0Fokus\u00a0\u2013\u00a0\u00a0der \u00a0bislang\u00a0auf\u00a0Themen\u00a0lag,\u00a0die\u00a0si ch\u00a0f\u00fcr\u00a0drittmittelfinanzierte\u00a0\nProjekte\u00a0der\u00a0Versorgungsforschung \u00a0eignen\u00a0\u2013\u00a0\u00a0zu\u00a0erweitern\u00a0und\u00a0in \u00a0seiner\u00a0Gr\u00f6\u00dfe\u00a0zu\u00a0wachsen.\u00a0\nK\u00fcnftig\u00a0steht\u00a0der\u00a0Beirat\u00a0somit\u00a0auch\u00a0f\u00fcr\u00a0eine\u00a0Beteiligung\u00a0an\u00a0Pro jekten\u00a0zur\u00a0Verf\u00fcgung,\u00a0die\u00a0die\u00a0\nWeiterentwicklung\u00a0der\u00a0Versorgung\u00a0a m\u00a0ZKJ\u00a0betreffen.\u00a0Eine\u00a0erste\u00a0M \u00f6glichkeit\u00a0besteht\u00a0\nbeispielsweise\u00a0in\u00a0der\u00a0Entwicklung \u00a0des\u00a0Kommunikationskonzepts\u00a0f\u00fc r\u00a0die\u00a0neue\u00a0Kinderklinik\u00a0bzw.\u00a0\nder\u00a0Entwicklung\u00a0zur\u00a0gesundheitskom petenzf\u00f6rdernden\u00a0Organisation .\u00a0In\u00a0diesem\u00a0\nZusammenhang\u00a0ist\u00a0die\u00a0Entwicklung\u00a0von\u00a0neuen\u00a0Informationsmaterial ien\u00a0f\u00fcr\u00a0Patient*innen\u00a0und\u00a0\nAngeh\u00f6rige\u00a0geplant.\u00a0Der\u00a0Beirat\u00a0kann\u00a0hier\u00a0einen\u00a0wichtigen\u00a0Beitra g\u00a0leisten,\u00a0um\u00a0z.B.\u00a0die\u00a0Themen\u00a0\nf\u00fcr\u00a0die\u00a0Produktion\u00a0entsprechende r\u00a0Materialien\u00a0auszuw\u00e4hlen,\u00a0die\u00a0 aus\u00a0der\u00a0Sicht\u00a0Betroffener\u00a0\nbesonders\u00a0relevant\u00a0sind.\u00a0Daf\u00fcr\u00a0i st\u00a0allerdings\u00a0eine\u00a0personelle\u00a0V erst\u00e4rkung\u00a0des\u00a0Beirats\u00a0\nnotwendig.\u00a0Die\u00a0Ansprechpartner*i nnen\u00a0(s.u.)\u00a0freuen\u00a0sich\u00a0\u00fcber\u00a0Hi nweise,\u00a0welche\u00a0Patient*innen\u00a0\noder\u00a0Eltern\u00a0Interesse\u00a0an\u00a0der\u00a0Mita rbeit\u00a0im\u00a0Beirat\u00a0haben\u00a0k\u00f6nnten. \u00a0\nThorsten\u00a0Langer,\u00a0Susanne\u00a0D\u00fcrr,\u00a0Anneke\u00a0Haddad\u00a0\n\u00a0\nWeitere\u00a0Informationen:\u00a0https:// pubmed.ncbi.nlm.nih.gov/36038462 /\u00a0\n\u00a0\n\u00a0\n\u00a0\nLongitudinale\u00a0Immunantwort\u00a0auf\u00a03\u00a0D osen\u00a0eines\u00a0Messenger\u2010RNA\u2010Impf stoffs\u00a0\ngegen\u00a0Coronavirus\u2010Erkrankungen\u00a0(COVID\u00a019)\u00a0bei\u00a0p\u00e4diatrischen\u00a0\nonkologischen\u00a0Patienten,\u00a0die \u00a0eine\u00a0Chemotherapie\u00a0erhalten \u00a0\u00a0\nKinder\u00a0und\u00a0Jugendliche\u00a0mit\u00a0onkologischen\u00a0Erkrankungen\u00a0unter\u00a0Che motherapie\u00a0haben\u00a0ein\u00a0\nerh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0schwerere\u00a0COVID\u201019\u00a0Verl\u00e4ufe\u00a0als\u00a0gleichaltri ge\u00a0gesunde\u00a0Kinder.\u00a0Ende\u00a02020\u00a0\nempfahl\u00a0die\u00a0STIKO\u00a0aufgrund\u00a0des\u00a0erh\u00f6hten\u00a0Risikos\u00a0die\u00a0Impfung\u00a0geg en\u00a0SARS\u2010CoV\u20102\u00a0f\u00fcr\u00a0alle\u00a0\nPatientinnen\u00a0und\u00a0Patienten\u00a0unter\u00a0C hemotherapie.\u00a0Die\u00a0Wirksamkeit \u00a0der\u00a0Impfungen\u00a0bei\u00a0Kindern\u00a0\nund\u00a0 Jugendlichen\u00a0 unter\u00a0 Chemotherapie\u00a0 war\u00a0 jedoch\u00a0 noch\u00a0 unklar.\u00a0 Es \u00a0w u r d e \u00a0d a h e r \u00a0e i n e \u00a0\nprospektive,\u00a0 longitudinale\u00a0 Beobachtungsstudie\u00a0 initiiert,\u00a0 um\u00a0 die \u00a0 humorale\u00a0 und\u00a0 zellul\u00e4re\u00a0\nImmunreaktion\u00a0von\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0unter\u00a0Chemotherapie\u00a0 zu\u00a0evaluieren.\u00a0An\u00a0der\u00a0\nStudie\u00a0 nahmen\u00a0 insgesamt\u00a0 21\u00a0 Jugendliche\u00a0 (13\u201017\u00a0 Jahre)\u00a0 mit\u00a0 versch iedenen\u00a0 onkologischen\u00a0\nErkrankungen\u00a0unter\u00a0intensiver\u00a0Chemotherapie\u00a0oder\u00a0Erhaltungschem otherapie\u00a0aus\u00a0Frankfurt,\u00a0\nM\u00fcnster\u00a0und\u00a0Freiburg\u00a0teil.\u00a0Sie\u00a0erhielten\u00a02\u00a0Impfungen\u00a0eines\u00a0mRNA \u2010Impfstoffes\u00a0(BioNTech/Pfizer)\u00a0\ninnerhalb\u00a0von\u00a03\u20106\u00a0Wochen\u00a0sowie\u00a0eine\u00a0weitere\u00a0Booster\u2010Impfung\u00a0nac h\u00a04\u00a0Wochen\u00a0bis\u00a06\u00a0Monaten.\u00a0\nVor\u00a0 Studienbeginn\u00a0 wurde\u00a0 zun\u00e4chst\u00a0 eine\u00a0 stattgehabte\u00a0 COVID\u201019\u2010Inf ektion\u00a0 ausgeschlossen.\u00a0\nAnschlie\u00dfend\u00a0wurde\u00a0die\u00a0Immunantwo rt\u00a0nach\u00a0den\u00a0jeweiligen\u00a0Impfung en\u00a0evaluiert.\u00a0Es\u00a0konnte\u00a0\ngezeigt\u00a0werden,\u00a0dass\u00a0die\u00a0meiste n\u00a0Patientinnen\u00a0und\u00a0Patienten\u00a0tro tz\u00a0Chemotherapie\u00a0nach\u00a03\u00a0\nImpfungen\u00a0sowohl\u00a0eine\u00a0humorale\u00a0als\u00a0auch\u00a0zellul\u00e4re\u00a0Immunreaktion \u00a0zeigten.\u00a0Die\u00a0Immunantwort\u00a0\nauf\u00a0die\u00a0Impfungen\u00a0war\u00a0insgesamt\u00a0st\u00e4rker\u00a0bei\u00a0Patientinnen\u00a0und\u00a0Pa tienten\u00a0mit\u00a0soliden\u00a0Tumoren\u00a0\nals\u00a0bei\u00a0denen\u00a0mit\u00a0onkologischen\u00a0Erkrankungen\u00a0des\u00a0blutbildenden\u00a0 Systems.\u00a0Ebenso\u00a0zeigten\u00a0die\u00a0\n9Jugendlichen,\u00a0die\u00a0w\u00e4hrend\u00a0der\u00a0weni ger\u00a0intensiven\u00a0Erhaltungschem otherapie\u00a0geimpft\u00a0wurden,\u00a0\neine\u00a0bessere\u00a0Immunreaktion\u00a0als\u00a0diejenigen,\u00a0die\u00a0intensivere\u00a0Chem otherapie\u00a0erhielten.\u00a0W\u00e4hrend\u00a0\nder\u00a0Studienteilnahme\u00a0traten\u00a0keine\u00a0 COVID\u2010Infektionen\u00a0bei\u00a0den\u00a0Jug endlichen\u00a0auf.\u00a0Eine\u00a0weitere\u00a0\nEvaluation\u00a0der\u00a0Patientinnen\u00a0und\u00a0Patienten\u00a0nach\u00a04.\u00a0Impfung\u00a0ist\u00a0g eplant.\u00a0\u00a0\nAnsprechpartner\u00a0am\u00a0ZKJ:\u00a0Prof.\u00a0Dr .\u00a0Simone\u00a0Hettmer,\u00a0PD\u00a0Dr.\u00a0Carste n\u00a0Speckmann\u00a0\n\u00a0\nWeitere\u00a0Informationen\u00a0unter:\u00a0h ttps://pubmed.ncbi.nlm.nih.gov/35 901198/\u00a0\n\u00a0\n\u00a0\nAVA\u2010PED\u2010301:\u00a0Eine\u00a0multizentrisch e,\u00a0randomisierte,\u00a0doppelblinde, \u00a0placebokontrollierte\u00a0Phase\u00a0\n3b\u00a0 Studie\u00a0 zur\u00a0 Evaluation\u00a0 der\u00a0 Wirksamkeit\u00a0 und\u00a0 Sicherheit\u00a0 von\u00a0 Ava trombopag\u00a0 bei\u00a0 der\u00a0\nBehandlung\u00a0von\u00a0p\u00e4diatrischen\u00a0Pat ienten\u00a0mit\u00a0Immunthrombozytopeni en\u00a0(\u22656\u00a0Monaten) \u00a0\n\u00a0\nImmunthrombozytopenien\u00a0 (ITP)\u00a0 sind\u00a0 erworbene\u00a0 Thrombozytopenien,\u00a0 welche\u00a0 durch\u00a0 eine\u00a0\nautoimmune\u00a0Reaktion\u00a0gegen\u00a0Thrombozyten\u00a0und\u00a0deren\u00a0Vorstufen\u00a0veru rsacht\u00a0werden.\u00a0Bei\u00a0einem\u00a0\nMangel\u00a0 an\u00a0 Thrombozyten\u00a0 besteht\u00a0 ein\u00a0 erh\u00f6htes\u00a0 Blutungsrisiko.\u00a0 Die \u00a0m e i s t e n \u00a0\nImmunthrombozytopenien\u00a0 im\u00a0 Kindesalter\u00a0 treten\u00a0 im\u00a0 Kleinkindalter\u00a0 auf\u00a0 und\u00a0 erholen\u00a0 sich\u00a0\nspontan.\u00a0Es\u00a0gibt\u00a0jedoch\u00a0auch\u00a0l\u00e4nger\u00a0anhaltende,\u00a0chronische\u00a0Verl \u00e4ufe.\u00a0In\u00a0vielen\u00a0F\u00e4llen\u00a0kann\u00a0man\u00a0\nzun\u00e4chst\u00a0 den\u00a0 spontanen\u00a0 Verlauf\u00a0 beobachten.\u00a0 Kommt\u00a0 es\u00a0 jedoch\u00a0 zu\u00a0 b esonders\u00a0 niedrigen\u00a0\nThrombozytenzahlen\u00a0 oder\u00a0 relevanten\u00a0 Blutungszeichen\u00a0 sind\u00a0 medikam ent\u00f6se\u00a0 Therapien\u00a0\nnotwendig.\u00a0 Zu\u00a0 den\u00a0 prim\u00e4ren\u00a0 Therapieoptionen\u00a0 z\u00e4hlen\u00a0 Immunglobuli ne\u00a0 und\u00a0 Steroide.\u00a0 Bei\u00a0\nlanganhaltenden\u00a0bzw.\u00a0chronischen\u00a0Thrombozytopenien\u00a0mit\u00a0niedrige n\u00a0Thrombozytenzahlen\u00a0\nund/oder\u00a0 Blutungszeichen\u00a0 kommen\u00a0 im\u00a0 Kindesalter\u00a0 unter\u00a0 anderem\u00a0 Th rombopoetin\u00a0 (TPO)\u2010\nRezeptor\u2010Agonisten\u00a0wie\u00a0Eltrombop ag\u00a0(p.o.)\u00a0oder\u00a0Romiplostim\u00a0(s.c .)\u00a0infrage,\u00a0die\u00a0eine\u00a0vermehrte\u00a0\nBildung\u00a0der\u00a0Blutpl\u00e4ttchen\u00a0stimulieren.\u00a0Teilweise\u00a0werden\u00a0auch\u00a0im munsuppressive\u00a0Therapien\u00a0\nangewandt.\u00a0Insgesamt\u00a0sind\u00a0die\u00a0Therapieoptionen\u00a0bei\u00a0Kindern\u00a0und\u00a0 Jugendlichen\u00a0jedoch\u00a0noch\u00a0\neingeschr\u00e4nkt.\u00a0\nAv atro mbo pag\u00a0(DO P T ELET \u00ae )\u00a0is t\u00a0ein\u00a0neuer,\u00a0o raler\u00a0T P O \u2010 Rezepto r\u2010 Ago nist,\u00a0der\u00a0ebenfalls\u00a0die\u00a0\nBildung\u00a0der\u00a0Thrombozyten\u00a0stimulie rt\u00a0und\u00a0bei\u00a0Erwachsenen\u00a0bereits \u00a0gute\u00a0Therapieergebnisse\u00a0\n(Thrombozyten\u00a0\u2265\u00a050000/\u00b5l)\u00a0gezeigt\u00a0hat.\u00a0Insbesondere\u00a0konnte\u00a0auch \u00a0eine\u00a0gute\u00a0Vertr\u00e4glichkeit\u00a0mit\u00a0\nwenig\u00a0Nebenwirkungen\u00a0gezeigt\u00a0werden.\u00a0Zudem\u00a0ist\u00a0die\u00a0orale\u00a0Applik ation\u00a0einfach\u00a0und\u00a0erleichtert\u00a0\neine\u00a0gute\u00a0Compliance.\u00a0\nDie\u00a0AVA\u2010PED\u2010301\u2010Studie\u00a0wurde\u00a0initiiert,\u00a0um\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0 Sicherheit\u00a0von\u00a0Avatrombopag\u00a0\nauch\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0mit\u00a0Thrombozytopenien\u00a0(\u22656\u00a0Mon aten)\u00a0nachzuweisen.\u00a0\nInsgesamt\u00a0sollen\u00a0international\u00a072\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0an\u00a0etw a\u00a050\u00a0Zentren\u00a0untersucht\u00a0\nwerden.\u00a0 Teilnehmen\u00a0 k\u00f6nnen\u00a0 Patient* i n n e n , \u00a0d i e \u00a0a u f \u00a0d i e \u00a0b i s h e r i g e n \u00a0 Therapien\u00a0 ein\u00a0\nunzureichendes\u00a0 Ansprechen\u00a0 gezeigt\u00a0 haben.\u00a0 Der\u00a0 Studieneinschluss\u00a0 ist\u00a0 nach\u00a0 Altersgruppen\u00a0\ngestaffelt.\u00a0Die\u00a0\u00e4lteste\u00a0Kohorte\u00a0(12\u201018\u00a0Jahre),\u00a0in\u00a0die\u00a0wir\u00a0eine\u00a0 unserer\u00a0Patientinnen\u00a0einschlie\u00dfen\u00a0\nkonnten,\u00a0ist\u00a0bereits\u00a0vollst\u00e4ndig.\u00a0Aktuell\u00a0k\u00f6nnen\u00a0noch\u00a0Kinder\u00a0vo n\u00a01\u201011\u00a0Jahren\u00a0eingeschlossen\u00a0\nwerden.\u00a0\u00a0\nZun\u00e4chst\u00a0werden\u00a0die\u00a0Kinder\u00a0und\u00a0Jugendlichen\u00a0f\u00fcr\u00a012\u00a0Wochen\u00a0mit\u00a0A vatrombopag\u00a0oder\u00a0einem\u00a0\nPlacebo\u00a0(Verh\u00e4ltnis\u00a03:1)\u00a0behande lt.\u00a0Dabei\u00a0werden\u00a0die\u00a0Thrombozyt enzahlen\u00a0sowie\u00a0m\u00f6gliche\u00a0\nNebenwirkungen\u00a0 engmaschig\u00a0 kontrolliert.\u00a0 Auch\u00a0 die\u00a0 Pharmakokineti k\u00a0 wird\u00a0 untersucht.\u00a0\nNebenher\u00a0f\u00fchren\u00a0die\u00a0Patient*innen\u00a0Tagebuch\u00a0\u00fcber\u00a0die\u00a0Einnahme\u00a0un d\u00a0Schmackhaftigkeit\u00a0der\u00a0\nTabletten\u00a0sowie\u00a0\u00fcber\u00a0auftretende\u00a0Beschwerden\u00a0oder\u00a0Blutungszeich en.\u00a0Nach\u00a0den\u00a0initialen\u00a012\u00a0\nWochen\u00a0 der\u00a0 Studie\u00a0 beginnt\u00a0 eine\u00a0 zweij\u00e4hrige\u00a0 offene\u00a0 Verl\u00e4ngerungs phase\u00a0 in\u00a0 der\u00a0 alle\u00a0\nPatient*innen\u00a0 das\u00a0 Verum\u00a0 erhalten \u00a0 k\u00f6nnen.\u00a0 Die\u00a0 Dosis\u00a0 wird\u00a0 jeweils \u00a0a b h \u00e4 n g i g \u00a0v o n \u00a0d e n \u00a0\nThrombozytenzahlen\u00a0(mit\u00a0dem\u00a0Ziel\u00a0\u2265\u00a050000/\u00b5l)\u00a0gesteuert.\u00a0\u00a0\nAnsprechpartnerin\u00a0am\u00a0ZKJ:\u00a0PD\u00a0Dr.\u00a0Brigitte\u00a0Strahm\u00a0\n\u00a0\nWeitere\u00a0Informationen:\u00a0www.clin icaltrials.gov:\u00a0NCT04516967\u00a010\u00a0\n\u00a0\n\u00a0\n\u00a0\nKlinische\u00a0Studien:\u00a0\u201eWer\u00a0macht\u00a0was\u00a0/\u00a0Wie\u00a0geht\u00a0das\u00a0?\u201c\u00a0\n \nIm\u00a010.\u00a0Teil\u00a0dieser\u00a0Reihe\u00a0beleuchten\u00a0wir\u00a0die\u00a0 Ethikkommission :\u00a0\u00a0\n\u00a0\nEine\u00a0Ethikkommission\u00a0(EK)\u00a0bewertet\u00a0Antr\u00e4ge\u00a0zur\u00a0Durchf\u00fchrung\u00a0kli nischer\u00a0Studien\u00a0von\u00a0\nArzneimitteln\u00a0und\u00a0Medizinprodukte n\u00a0nach\u00a0ethischen\u00a0Gesichtspunkt en.\u00a0Damit\u00a0sollen\u00a0in\u00a0erster\u00a0\nLinie\u00a0die\u00a0Rechte\u00a0und\u00a0die\u00a0Sicherhei t\u00a0der\u00a0Patient*innen\u00a0gew\u00e4hrlei stet\u00a0werden.\u00a0Neben\u00a0dem\u00a0\nStudienprotokoll\u00a0wird\u00a0auch\u00a0die\u00a0Qualifikation\u00a0der\u00a0Pr\u00fcf\u00e4rzt*innen \u00a0und\u00a0der\u00a0Pr\u00fcfstelle\u00a0bewertet.\u00a0\nAlle\u00a0Unterlagen,\u00a0die\u00a0Patient*inne n\u00a0im\u00a0Verlauf\u00a0der\u00a0Studie\u00a0erhalt en,\u00a0wie\u00a0die\u00a0\nPatienteninformation,\u00a0die\u00a0Einwilligungserkl\u00e4rung,\u00a0Werbung,\u00a0die\u00a0 Proband*innenversicherung\u00a0\nund\u00a0die\u00a0Aufwandsentsch\u00e4digung,\u00a0werden\u00a0von\u00a0der\u00a0Ethikkommission\u00a0g epr\u00fcft.\u00a0\u00a0\nErst\u00a0nach\u00a0Genehmigung\u00a0durch\u00a0die \u00a0Bundesoberbeh\u00f6rde\u00a0(BfArM\u00a0oder\u00a0P EI)\u00a0und\u00a0nach\u00a0\nzustimmender\u00a0Bewertung\u00a0durch\u00a0d ie\u00a0Ethikkommission\u00a0darf\u00a0eine\u00a0klin ische\u00a0Pr\u00fcfung\u00a0beginnen.\u00a0\nNach\u00a0der\u00a0Ersteinreichung\u00a0m\u00fcssen\u00a0 Amendments,\u00a0ein\u00a0Pr\u00fcfgruppenwech sel\u00a0oder\u00a0Pr\u00fcfstellen\u2010\nNachmeldungen\u00a0bei\u00a0der\u00a0EK\u00a0nachtr\u00e4glich\u00a0eingereicht\u00a0werden.\u00a0\nDie\u00a0Ethikkommission\u00a0hat\u00a0auch\u00a0eine\u00a0beratende\u00a0Funktion\u00a0bei\u00a0der\u00a0Er stellung\u00a0eines\u00a0neuen\u00a0\nStudienprotokolls\u00a0und\u00a0im\u00a0Rahmen\u00a0d er\u00a0berufsrechtlichen\u00a0Beratungs pflicht\u00a0f\u00fcr\u00a0die\u00a0\nPr\u00fcf\u00e4rzt*innen,\u00a0die\u00a0Non\u2010AMG/Non\u2010MPDG\u2010Studien,\u00a0wie\u00a0Register\u00a0und\u00a0 Forschungsvorhaben,\u00a0\ndurchf\u00fchren\u00a0oder\u00a0daran\u00a0teilnehmen\u00a0m\u00f6chten.\u00a0\u00a0\nEthikkommissionen\u00a0arbeiten\u00a0in\u00a0Deu tschland\u00a0interdisziplin\u00e4r.\u00a0Sie \u00a0sind\u00a0je\u00a0nach\u00a0Satzung\u00a0aus\u00a0\nVertreter*innen\u00a0der\u00a0Medizin,\u00a0N atur\u2010\u00a0und\u00a0Rechtswissenschaften,\u00a0P hilosophie,\u00a0Theologie,\u00a0\nBiometrie\u00a0und\u00a0Laien\u00a0zusammengesetzt.\u00a0Damit\u00a0wird\u00a0angestrebt,\u00a0all e\u00a0zu\u00a0ber\u00fccksichtigenden\u00a0\nAspekte\u00a0in\u00a0die\u00a0abschlie\u00dfende\u00a0Bew ertung\u00a0einflie\u00dfen\u00a0zu\u00a0lassen.\u00a0\nDie\u00a0federf\u00fchrende\u00a0Ethikkommission\u00a0ist\u00a0bei\u00a0klinischen\u00a0Pr\u00fcfungen, \u00a0die\u00a0gem\u00e4\u00df\u00a0der\u00a0Richtlinie\u00a0\n2001/20/EG\u00a0durchgef\u00fchrt\u00a0werden,\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Leitung\u00a0der\u00a0klinisc hen\u00a0Pr\u00fcfung\u00a0(LKP)\u00a0zust\u00e4ndige\u00a0\nEthikkommission.\u00a0Die\u00a0Richtlinie\u00a02001/20/EG\u00a0wird\u00a0ab\u00a0Januar\u00a02023\u00a0 durch\u00a0die\u00a0EU\u00a0Regulation\u00a0\n536/2014\u00a0abgel\u00f6st.\u00a0Unter\u00a0der\u00a0EU\u00a0Regulation\u00a0536/2014\u00a0stellt\u00a0der\u00a0 Sponsor\u00a0nun\u00a0seinen\u00a0Antrag\u00a0\nzur\u00a0Durchf\u00fchrung\u00a0einer\u00a0klinischen\u00a0Pr\u00fcfung\u00a0mit\u00a0Arzneimitteln\u00a0bei \u00a0mono\u2010\u00a0und\u00a0multinationalen\u00a0\nStudien\u00a0nur\u00a0noch\u00a0einmalig\u00a0\u00fcber\u00a0 das\u00a0zentrale\u00a0Online\u2010Portal\u00a0CTIS\u00a0 (Clinical\u00a0Trials\u00a0Information\u00a0\nSystem)\u00a0bei\u00a0der\u00a0EMA.\u00a0Es\u00a0wird\u00a0keinen\u00a0LKP\u00a0mehr\u00a0geben\u00a0und\u00a0die\u00a0Zute ilung\u00a0zu\u00a0einer\u00a0\nfederf\u00fchrenden\u00a0Ethikkommission\u00a0erfolgt\u00a0\u00fcber\u00a0den\u00a0sogenannten\u00a0Ges ch\u00e4ftsverteilungsplan\u00a0in\u00a0\nder\u00a0Reihenfolge\u00a0der\u00a0Listungen.\u00a0Dabei\u00a0ber\u00fccksichtigt\u00a0der\u00a0Gesch\u00e4f tsverteilungsplan\u00a0\ninsbesondere\u00a0die\u00a0Gesamtzahl\u00a0der \u00a0registrierten\u00a0Ethikkommissionen \u00a0sowie\u00a0ihre\u00a0jeweilige\u00a0\nj\u00e4hrliche\u00a0Kapazit\u00e4t.\u00a0Die\u00a0Zust\u00e4ndigkeit\u00a0der\u00a0Ethikkommission\u00a0f\u00fcr\u00a0 einen\u00a0Antrag\u00a0bei\u00a0klinischen\u00a0\nStudien\u00a0hat\u00a0daher\u00a0keinen\u00a0zwingende n\u00a0lokalen\u00a0Bezug\u00a0mehr\u00a0zum\u00a0Antr agsteller.\u00a0Der\u00a0Antrag\u00a0wird\u00a0\nausschlie\u00dflich\u00a0von\u00a0der\u00a0zugeteilt en\u00a0zentralen\u00a0Ethikkommission\u00a0be wertet,\u00a0die\u00a0lokalen\u00a0\nEthikkommissionen\u00a0werden\u00a0nicht\u00a0me hr\u00a0einbezogen.\u00a0Sachverst\u00e4ndige \u00a0k\u00f6nnen\u00a0allerdings\u00a0unter\u00a0\nEinhaltung\u00a0der\u00a0gesetzlich\u00a0engen\u00a0Fristen\u00a0hinzugezogen\u00a0werden.\u00a0\u00a0\nBei\u00a0sonstigen,\u00a0non\u2010AMG,\u00a0nicht\u2010in terventionellen\u00a0und\u00a0MPDG\u2010Studie n\u00a0sind\u00a0jedoch\u00a0weiterhin\u00a0die\u00a0\nden\u00a0Pr\u00fcfstellen\u00a0zugeordneten\u00a0lo kalen\u00a0Ethikkommissionen\u00a0zust\u00e4ndi g.\u00a0\n \n\u00a0\n\u00a0\nKurz\u00a0berichtet\u00a0\n\u00a0\nWir\u00a0wachsen\u00a0nicht\u00a0nur\u00a0an\u00a0unseren\u00a0Aufgaben,\u00a0sondern\u00a0auch\u00a0im\u00a0Team !\u00a011Das\u00a0ZKJ\u2010Studienb\u00fcro\u00a0begr\u00fc\u00dft\u00a0drei\u00a0neue\u00a0 Studienassistentinnen \u00a0und\u00a0eine\u00a0neue\u00a0\nProjektmanagerin :\u00a0\nAnna\u2010Lena\u00a0D\u00e4schle,\u00a0Fachkinderkrankenpflegerin\u00a0f\u00fcr\u00a0p\u00e4d.\u00a0Intensivpflege,\u00a0ist\u00a0Studi enassistentin\u00a0\nmit\u00a0dem\u00a0Schwerpunkt\u00a0Hirntumorstudien\u00a0und\u2010register.\u00a0\nChristine\u00a0Braun ,\u00a0Kinderkrankenschwester\u00a0und\u00a0Study\u00a0Nurse,\u00a0wird\u00a0die\u00a0neue\u00a0TRACE\u2010Studie\u00a0sowie\u00a0\nStudien\u00a0und\u00a0Register\u00a0bei\u00a0Soliden\u00a0Tumoren\u00a0betreuen.\u00a0\nNadine\u00a0Hug ,\u00a0Gesundheits\u2010\u00a0und\u00a0Krankenpflegerin,\u00a0ist\u00a0zust\u00e4ndig\u00a0f\u00fcr\u00a0die\u00a0neue \u00a0Gentherapiestudie\u00a0\nDTX401\u2010CL301\u00a0bei\u00a0Glykogenspeicherkrankheit\u00a0Typ\u00a01a.\u00a0\nDr.\u00a0Sandra\u00a0Dieni ,\u00a0Neurowissenschaftlerin,\u00a0\u00fcberni mmt\u00a0regulatorische,\u00a0vertragliche\u00a0und\u00a0\nfinanzielle\u00a0Aufgaben\u00a0des\u00a0Projektmanagements.\u00a0\nWir\u00a0freuen\u00a0uns\u00a0\u00fcber\u00a0eure\u00a0Unterst \u00fctzung\u00a0und\u00a0auf\u00a0die\u00a0Zusammenarbe it!\u00a0\nUnsere\u00a0Leserbefragung\u00a0ist\nweiterhin\u00a0offen !\nIhr\u00a0Feedback\u00a0zum\u00a0Newsletter\u00a0ist\nuns\u00a0wichtig!\nhttps://www.surveymonkey.de/r/V67GD7\n2 \nMit\u00a0diesem\u00a0Logo\u00a0kennzeichnen\u00a0wir\u00a0Beitr\u00e4ge,\u00a0die\u00a0wir\u00a0als\u00a0besonder s\u00a0in\nf\u00fcr\u00a0Lehrkrankenh\u00e4user\u00a0und\u00a0niedergelassene\u00a0\u00c4rzte\u00a0erachten.\u00a0\n12\u00a0\nPlatzierung\u00a0des\u00a0Newsletters \u00a0\nIntranet\u00a0ZKJ:\u00a0 \u00a0\nhttp://intranet.ukl.uni\u2010freiburg.de/organisation\u2010einrichtungen/ departments/zkj/mitarbeiter\u2010\ninfos/studienb\u00fcro/ \u00a0\nInternet: \u00a0\nhttps://www.uniklinik\u2010freiburg.de/kinderklinik/forschung\u2010und\u2010kl inische\u2010studien/klinische\u2010studien\u2010\nund\u2010register/aktuelles.html\u00a0\n\u00a0\n\u00dcbersicht\u00a0der\u00a0laufenden\u00a0Klinischen\u00a0Studien\u00a0am\u00a0ZKJ \u00a0\nIntranet\u00a0ZKJ: \u00a0\nhttp://intranet.ukl.uni\u2010freiburg.de/organisation\u2010einrichtungen/ departments/zkj/mitarbeiter\u2010\ninfos/studienb\u00fcro/ \u00a0\nInternet: \u00a0\nhttps://www.uniklinik\u2010freiburg.de/kinderklinik/forschung\u2010und\u2010kl inische\u2010studien/klinische\u2010studien\u2010\nund\u2010register/uebersicht\u2010klinische\u2010studien.html \u00a0\n\u00a0\n\u00a0\n\u00a0\nDas\u00a0Team\u00a0des\u00a0Studienb\u00fcros\u00a0steht\u00a0f\u00fcr\u00a0R\u00fcckfragen\u00a0gerne\u00a0zur\u00a0Verf\u00fcg ung\u00a0!\u00a0\n\u00a0\n\u00a0\nzkj.studien@uniklinik\u2010freiburg.de \u00a0\nRedaktion:\u00a0Susanne\u00a0Gr\u00fcninger,\u00a0PD\u00a0Dr.\u00a0Simone\u00a0Hettmer \u00a0\nAusf\u00fchrliche\u00a0Beitr\u00e4ge:\u00a0Prof.\u00a0Dr.\u00a0Sarah\u00a0Gr\u00fcnert,\u00a0Eva\u2010Maria\u00a0Korne mann,\u00a0Prof.\u00a0Dr.\u00a0Thorsten\u00a0\nLanger,\u00a0Susanne\u00a0Gr\u00fcninger,\u00a0Nicolas\u00a0Enriquez\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}